1. Home
  2. IMSR vs CCCC Comparison

IMSR vs CCCC Comparison

Compare IMSR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMSR

Terrestrial Energy Inc.

N/A

Current Price

$8.32

Market Cap

233.8M

Sector

N/A

ML Signal

N/A

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.45

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMSR
CCCC
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.8M
240.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
IMSR
CCCC
Price
$8.32
$2.45
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.50
AVG Volume (30 Days)
1.8M
1.4M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$30,108,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1234.25
N/A
52 Week Low
$7.52
$1.09
52 Week High
$31.50
$4.70

Technical Indicators

Market Signals
Indicator
IMSR
CCCC
Relative Strength Index (RSI) N/A 46.82
Support Level N/A $2.50
Resistance Level N/A $2.69
Average True Range (ATR) 0.00 0.18
MACD 0.00 -0.02
Stochastic Oscillator 0.00 10.21

Price Performance

Historical Comparison
IMSR
CCCC

About IMSR Terrestrial Energy Inc.

Terrestrial Energy Inc is an industry-leading technology company committed to delivering reliable, emission-free, and cost-competitive nuclear energy with a transformative advanced reactor, the Integral Molten Salt Reactor (IMSR). Its mission is to transform global energy markets by commercializing its IMSR Plant, which will deliver low-carbon electricity and industrial heat with superior economics, speed to deployment, and siting flexibility.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: